FAB

Fusion Antibodies Plc

7.00
1.38 (24.44%)
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  1.38 24.44% 7.00 2,842,192 16:20:56
Bid Price Offer Price High Price Low Price Open Price
6.75 7.25 7.125 5.625 5.625
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceutical Preparations 4.80 -1.20 -4.60 - 1.82
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:35 O 110,000 7.00 GBX

Fusion Antibodies (FAB) Latest News

Fusion Antibodies (FAB) Discussions and Chat

Fusion Antibodies Forums and Chat

Date Time Title Posts
06/6/202316:04☆ Fusion Antibodies: from discovery to Clinical supply ☆3,365
28/10/202014:27NEW FAB Fusion Antibodies The Next AVCT53
18/9/202015:23Fusion Antibody II51
17/9/202009:25COVID. RAPID PROGRESS MADE. Ј3M RAISED58
08/2/201221:34Fabio Capello Resigns.......9

Add a New Thread

Fusion Antibodies (FAB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:07:357.00110,0007,700.00O
15:45:577.001,613112.91UT
15:29:567.002,729191.03O
15:29:486.9740,0002,788.00O
15:29:486.9740,0002,788.00O

Fusion Antibodies (FAB) Top Chat Posts

Top Posts
Posted at 05/6/2023 14:50 by clocktower
Well of course they want to control costs now Bigjock36 , as I am sure they want to stretch out what they have left just so they can keep up the pretence that this business is going to be a block buster - one day!

imo- the thing that has and is likely to get busted is shareholders money.

We are getting closer to the raise price as some might still be able to take a small profit I guess - how long before it goes sub 5p is the question.

What do you think is the current monthly burn rate with such a small revenue stream is?

Posted at 02/6/2023 15:43 by clocktower
Bigjock36 - Last year they also said they had sufficient funds to the point of breakeven.

So can you really believe a word they say?

Bear in mind they are draining cash each and every day and could not even get shareholders to put up the 500k they we hoping for at 5p a share.

While this was a good turn on the day of the huge discount, the chance of survival while the BOD feed themselves are as narrow as the eye of a needle impo.

Now they have all the funds don't you think it would be good to tell us all how much cash is in the kitty in total and how much is owed in total, along with revenue invoiced?

Not a chance of them doing so is there!!!

Beware!

Posted at 22/5/2023 16:11 by blackhorse23
Another NI company HARL is doing very good , put me off to invest in here because company doesn't preserve shareholders value , placing 85% discounts price is awful
Posted at 20/5/2023 20:36 by hedgehog 100
What is fair value for FAB at the moment?

Let's try some robust valuation analysis.


Assuming full subscription for the 41,171,746 fundraising shares, added to existing 26,014,946 shares, then FAB will have 67,186,692 shares in issue. At 5p/share that would be a market cap. of c. £3.6M.; and c. £4.956M. at the current share price of 7.375p.

The company's H1 cash-burn was £800K., and the net fundraising cash if full subscription will be c. £1.42M.

It plans to cut costs, but revenue is collapsing: down massively to min. £2.8M. in 2023, but with about two thirds of that in H1.

So current annualised revenue based on H2 is probably below £2M., and the cash looks like it will probably be burnt within a year.

The CRO sector is very fragmented and competitive, and with reduced investment in the broader biotech sector, margins could come under pressure, to compound falling revenues.

From Wikipedia:-

" ... Organizations who have had success in working with a particular CRO in a particular context (e.g. therapeutic area) might be tempted or encouraged to expand their engagement with that CRO into other, unrelated areas; however, caution is required as CROs are always seeking to expand their experience and success in one area cannot reliably predict success in unrelated areas that might be new to the organization.[5] ...

As of 2013, there were over 1,100 CROs in the world, despite continued trends toward consolidation. Many CROs have been acquired while others have gone out of business.[9] ..."

https://en.wikipedia.org/wiki/Contract_research_organization


By way of comparison with what you could get elsewhere for a market cap. of £5M., NWT (market cap. £5.015M.at 53.5p) announced a positive trading update this week:-

17/05/2023 07:00 UK Regulatory (RNS & others) Newmark Security PLC Year-end trading update LSE:NWT Newmark Security Plc

"Continued revenue growth and a return to profitability

Newmark Security plc (AIM: NWT), a leading provider of electronic, software and physical security systems, today provides an update on trading for the year ended 30 April 2023 ("FY23"), reaffirming the Company's return to profitability. ..."

https://uk.advfn.com/stock-market/london/newmark-security-NWT/share-news/Newmark-Security-PLC-Year-end-trading-update/91085287

NWT's FY revenue is expected to be £20M.+, & pre-tax profit £1M.+.

It's outlook is buoyant, and there's plenty of business for everyone.

Posted at 20/5/2023 10:40 by hedgehog 100
JakNife 6 Apr '23 - 18:29 - 3279 of 3333 0.010000 4 1
"Here's another hugely dilutive placing that's been agreed in the sector:
Https://www.investegate.co.uk/allergy-therapeutics--agy-/rns/-40.75-million-facility-with-equity-financing/202304061401016719V/
It's a chunky raise but at 1p it's an 84% discount to the closing price before it was previously suspended.
All arrows point to a fund raise for FAB that materially dilutes current shareholders.
JakNife"

Well done to JakNife ... his AGY example was even the precise % discount as FAB's.


dave454519 May '23 - 10:15 - 3283 of 3333 0 1 1
"Bloody hell that is savage.
At least they did not have the nerve to say they were "pleased" to announce"

Not in yesterday's first RNS Dave, but they still managed to get in two 'pleased to say/announce' yesterday:-

19/05/2023 10:00 UK Regulatory (RNS & others) Fusion Antibodies PLC Placing, Subscription and Retail Offer LSE:FAB Fusion Antibodies Plc
" ... Fusion Antibodies CEO, Adrian Kinkaid said : "We are pleased to say that we have been able to raise funds in an extremely challenging market, ..." ..."
https://uk.advfn.com/stock-market/london/fusion-antibodies-FAB/share-news/Fusion-Antibodies-PLC-Placing-Subscription-and-Re/91112794

19/05/2023 10:01 UK Regulatory (RNS & others) Fusion Antibodies PLC REX Retail Offer LSE:FAB Fusion Antibodies Plc
"Fusion Antibodies plc (AIM: FAB) is pleased to announce a retail offer via REX (the "REX Retail Offer") of ordinary shares ("Ordinary Shares") of 4 pence each in the capital of the Company (the "REX Retail Offer Shares")
... The issue price of the Placing Shares and Subscription Shares is 5 pence (the "Issue Price"). The price of the REX Retail Offer Shares is equal to the Issue Price. ..."
https://uk.advfn.com/stock-market/london/fusion-antibodies-FAB/share-news/Fusion-Antibodies-PLC-REX-Retail-Offer/91112824


volsung 19 May '23 - 10:20 - 3288 of 3333 0 0 1
"Not the best Belfast share"

No, but the tiny number of London-listed N.I. shares includes former 15-bagger Kainos (KNOS) (still currently an 8.8-bagger from its 2015 IPO price of 139p); and FD Technologies (FDP) - currently a 37.6-bagger from its 2002 IPO price of 50p.

See the "Rockpool Acquisitions (ROC)" thread for details (it's a Northern Ireland shell company currently arranging a RTO):-
https://uk.advfn.com/cmn/fbb/thread.php3?id=41672308&from=1

Posted at 19/5/2023 22:14 by mr macgregor
Mr MacGregor - 27 Feb 2022 - 17:20:23 - 2149 of 3332 ☆ Fusion Antibodies: from discovery to Clinical supply ☆ - FAB
Whatsthepoint is certainly well named, and an idiot as evidenced by holding shares in this donkey. Simon Douglas poundshop chairman of FAB and ODX, CEOs a blur. Massive red flags. You have been warned.

Posted at 19/5/2023 19:28 by timbo003
>>>SSB

Yes, I was inside on this one (Project Hazel) and bought a few in the placing (EIS qualifying). I might buy a few more in the REX offer too should the price remains at a decent premium to the placing price

Posted at 03/5/2023 14:42 by cbeadle
Looking frisky at the moment for FAB
Posted at 06/4/2023 18:29 by jaknife
Here's another hugely dilutive placing that's been agreed in the sector:

Https://www.investegate.co.uk/allergy-therapeutics--agy-/rns/-40.75-million-facility-with-equity-financing/202304061401016719V/

It's a chunky raise but at 1p it's an 84% discount to the closing price before it was previously suspended.

All arrows point to a fund raise for FAB that materially dilutes current shareholders.

JakNife

Posted at 14/9/2022 08:39 by clocktower
A bit of support today, maybe WTP and his pals are buying in a few today to uphold the share price (or recover what they sold at a higher price maybe).

The company will have to come out with some very positive news if they want the share price stop the slide over the longer term imo.

DYOR.

Fusion Antibodies share price data is direct from the London Stock Exchange
Your Recent History
LSE
FAB
Fusion Ant..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230606 16:36:06